Mr. Narachi joined the Orexigen management team as President and Chief Executive Officer in March 2009. Michael has over 24 years of biotechnology and pharmaceutical experience across a broad range of functions including clinical development, commercialization, strategic business development and planning. Prior to joining Orexigen, Narachi served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company and Executive Chairman of the Board of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Narachi retired as an officer and Vice President and General Manager of Amgen's Anemia Business. Throughout his 20 years at Amgen, Narachi held various positions including: Product Development Team Leader for NEUPOGEN® Director of Clinical Operations in Thousand Oaks, Calif., and Cambridge, United Kingdom; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He is also Chairman of AMAG Pharmaceuticals, Inc. Mr. Narachi received a BS in biology and an MA in biology and genetics from the University of California at Davis. He also received an MBA from the Anderson Graduate School of Management at University of California, Los Angeles.